Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zopiclone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Usual sleep apnea and CPAP care Sleep apnea OSR Medical Treatment Plan© |
| zopiclone | EXPERIMENTAL | Sleep apnea OSR Medical Treatment plan © |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | 3.75-7.5mg 14 doses 4 weeks |
| Zopiclone | DRUG | 3.75-7.5mg 14 doses 4 weeks |
Inclusion Criteria: * MD diagnosis of obstructive sleep apnea * No previous use of CPAP * No concurrent use of hypnotic medication Exclusion Criteria: * Fatal comorbidities (i.e., life expectancy less than 6 months) * Contraindications for CPAP use * Pregnancy * Liver Failure
Zopiclone is being studied for use in Obstructive Sleep Apnea to improve compliance with Continuous Positive Airway Pressure (CPAP) therapy. It is a small molecule in Phase 3 clinical development, evaluated in a randomized, double-blind, placebo-controlled trial.
Zopiclone is being developed by OSR Holdings, Inc., a company traded under the ticker OSRH. The drug is currently in Phase 3 clinical development for Obstructive Sleep Apnea.
Zopiclone is in Phase 3 clinical development. It is an investigational drug being studied for Obstructive Sleep Apnea, and it is not yet approved for this use.
Zopiclone has one completed Phase 3 clinical trial, identified as NCT01369576, titled 'Effect of Zopiclone on Compliance With Continuous Positive Airway Pressure in Obstructive Sleep Apnea.' The trial enrolled 264 participants in Canada.
Zopiclone is a separate drug from eszopiclone. Zopiclone is being developed by OSR Holdings, Inc. for Obstructive Sleep Apnea, while eszopiclone is a different compound. No alternative names for Zopiclone have been established in this context.